Featured Research

from universities, journals, and other organizations

While Some Immune Cells Aim To Fight Cancer, Others Hold Them In Check

Date:
September 17, 2002
Source:
The Wistar Institute
Summary:
Many cancer patients generate immune cells capable of specifically attacking their tumors, but the cells rarely do, in fact, target a patient's cancer. What prevents these potentially helpful cells from taking action? And is there anything that might be done to unleash them? The attack cells - known as cytolytic T cells - are prevented from acting by a second set of immune cells called regulatory T cells, according to a new study from investigators at The Wistar Institute.

PHILADELPHIA - Many cancer patients generate immune cells capable of specifically attacking their tumors, but the cells rarely do, in fact, target a patient's cancer. What prevents these potentially helpful cells from taking action? And is there anything that might be done to unleash them?

The attack cells - known as cytolytic T cells - are prevented from acting by a second set of immune cells called regulatory T cells, according to a new study from investigators at The Wistar Institute. The research also shows that the regulatory T cells communicate their message of restraint to the cytolytic T cells at a distance, via a messenger chemical called TGF-beta. A report on the study appears in the September 15 issue of Cancer Research.

Previous work has focused on ways to stimulate the cytolytic T cells to act, but the new study suggests that other approaches to bringing them into the battle against cancer might be more effective. For example, a drug that inactivates the regulatory T cells or that blocks the TGF-beta chemical message they send might free the cytolytic T cells to attack a patient's tumor.

"We've known for some time that cancer patients can generate T cells able to attack their tumors," says immunologist Dorothee Herlyn, D.V.M., D.Sc., a professor at The Wistar Institute and senior author on Cancer Research study. "What we discovered in this study is that those patients also produce negatively regulating cells at the same time that keep the attacking T cells in check. The existence of these regulatory cells may help explain how tumors are able to evade the immune system. They also represent a new starting point for thinking about novel anti-cancer treatments."

The current study evolved somewhat by chance. Using cells from a human colorectal cancer patient, Herlyn's laboratory team was working to identify T cells with cancer-fighting capabilities and isolate them from other types of immune cells. At one point, one of her coworkers suggested combining different groups of isolated cell types to look for interactions between them.

"We put these two different types of immune cell together, one of which killed cancer cells in culture, the other of which did not," Herlyn recalls. "When we did, we were stunned to see that the one that had previously killed cancer cells no longer did so."

Adequately explaining the mechanisms underlying that observation required several years of additional study, she says.

The lead author on the Cancer Research study is Rajasekharan Somasundaram, Ph.D., at The Wistar Institute. The other Wistar-based coauthors are Lutz Jacob, Rolf Swoboda, Ph.D., Laura Caputo, Hong Song, Saroj Basak, David Peritt, Dewei Cai, Brigitte Birebent, Jin Kim, and Klara Berencsi. Collaborators on the study are Dimitri Monos, Ph.D., at the Hospital of the University of Pennsylvania, Francesco Marincola, M.D., at the National Cancer Institute, and Ellen Bloome and Michael Mastrangelo, M.D., a professor of medicine at Thomas Jefferson University. The research was supported by grants from the National Institutes of Health.

The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Center - one of only eight focused on basic research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.


Story Source:

The above story is based on materials provided by The Wistar Institute. Note: Materials may be edited for content and length.


Cite This Page:

The Wistar Institute. "While Some Immune Cells Aim To Fight Cancer, Others Hold Them In Check." ScienceDaily. ScienceDaily, 17 September 2002. <www.sciencedaily.com/releases/2002/09/020917071211.htm>.
The Wistar Institute. (2002, September 17). While Some Immune Cells Aim To Fight Cancer, Others Hold Them In Check. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2002/09/020917071211.htm
The Wistar Institute. "While Some Immune Cells Aim To Fight Cancer, Others Hold Them In Check." ScienceDaily. www.sciencedaily.com/releases/2002/09/020917071211.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins